Calcium channel blockers in the spectrum of antihypertensive agents

Bibliography

• CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA (2003) 289(19):2560-2572.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION,INTERNATIONAL SOCIETY OF HYPERTENSION WRITING GROUP: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on the management of hypertension. J. Hypertens. (2003) 21(11):1983-1992.
   PubMed Web of Science ®Google Scholar
• GUIDELINES COMMITTEE: 2003 Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21(5):1011-1053.
   PubMed Web of Science ®Google Scholar
• WILLIAMS B, POULTER NR, BROWN MJ et al.: The BHS Guidelines Working Party Guidelines for the Management of Hypertension: report of the Fourth Working Party of the British Hypertension Society 2004 – BHS IV. J. Hum. Hypertens. (2004) 18(3):139-185.
   PubMed Web of Science ®Google Scholar
• NEATON JD, GRIMM RH JR, PRINEAS RJ et al. for the treatment of mild hypertension study research group: Treatment of Mild Hypertension Study: final results. JAMA (1993) 270(6):713-722.
   PubMed Web of Science ®Google Scholar
• CHAUDHRY SI, KRUMHOLZ HM, FOODY JM: Systolic hypertension in older persons. JAMA (2004) 292(9):1074-1080.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, THIJS L, FAGARD RH et al.: Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension (1998) 32(3):410-416.
   PubMed Web of Science ®Google Scholar
• FLACK JM, SICA DA: Therapeutic considerations in the African American patients with hypertension: considerations with calcium channel blocker therapy. J. Clin. Hypertens. (2005) 7(4Supp1):9-14.
   Google Scholar
• BREWSTER LM, VAN MONTFRANS GA, KLIJNEN J: Systematic review: antihypertensive drug therapy in black patients. Ann. Int. Med. (2004) 141(8):614-627.
   PubMed Web of Science ®Google Scholar
• TURNBULL F, NEAL B, ALGERT C, CHALMERS J, WOODWARD M, MACMAHON S: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet (2003) 362(9395):1527-1535.
   PubMed Web of Science ®Google Scholar
• STAESSEN J, LI Y, THIJS L, WANG J-G: Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials. Hypertens. Res. (2005) 28(5):385-407.
   PubMed Web of Science ®Google Scholar
• PSATY B, LUMLEY T, FURBERG C et al.: Health outcomes associated with various antihypertensive therapies used as first-lines agents. A network meta-analysis. JAMA (2003) 289(19):2534-2544.
   PubMed Web of Science ®Google Scholar
• PITT B, BYINGTON R, FURBERG C et al. FOR THE PREVENT INVESTIGATORS: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation (2000) 102(13):1503-1510.
   PubMed Web of Science ®Google Scholar
• STAESSEN J, FAGARD R, THIJS L et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension in Europe. Lancet (1997) 350(9080):757-764.
   PubMed Web of Science ®Google Scholar
• DENS J, DESMET W, COUSSEMENT P et al.: Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal angioplasty (results of the NICOLE study). Am. J. Cardiol. (2001) 87(1):28-33.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345(12):861-869.
   PubMed Web of Science ®Google Scholar
• BERL T, HUNSACKER LB, LEWIS JB et al.: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with Type 2 diabetes and overt nephropathy. Ann. Int. Med. (2003) 138(7):542-549.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, LIBBY P et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary heart disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA (2004) 292(18):2217-2226.
   PubMed Web of Science ®Google Scholar
• POOLE-WILSON PA, LUBSEN J, KIRWAN BA et al.: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial) randomized controlled trial. Lancet (2004) 364(9437):849-857.
   PubMed Web of Science ®Google Scholar
• DENS JA, DESMET WJ, COUSSEMENT P et al.: Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart (2003) 89(8):887-892.
   PubMed Web of Science ®Google Scholar
• SICA DA: Calcium channel blockers: a more expansive treatment role. J. Hypertens. (2005) 7(4 Suppl. 1):2-4.
   Google Scholar
• ZANCHETTI Z, BOND G, HENNIG M et al.: Calcium antagonist lacidipine slows down progression of asymptomatic carotid stenosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA): a randomized, double-blind, long-term trial. Circulation (2002) 106(19):2422-2427.
   PubMed Web of Science ®Google Scholar
• NATIONAL INTERVENTION COOPERATIVE STUDY IN ELDERLY HYPERTENSIVES STUDY GROUP: Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension (1999) 34(5):1129-1133.
   PubMed Web of Science ®Google Scholar
• ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. JAMA (2002) 288(23):2981-2987.
   PubMed Web of Science ®Google Scholar
• HANSSON L, LINDHOLM L, EKBOM T et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet (1999) 354(9192):1751-1756.
   PubMed Web of Science ®Google Scholar
• BLACK H, ELLIOTT W, GRANDITS G et al.: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA (2003) 289(16):2073-2082.
   PubMed Web of Science ®Google Scholar
• BROWN M, PALMER C, CASTAIGNE A et al.: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet (2000) 356(9227):366-372.
   PubMed Web of Science ®Google Scholar
• HANSSON L, HEDNER T, LUND-JOHANSEN P et al.: Randomised trial of effects of calcium-antagonists compared with diuretics and β blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet (2000) 356(9227):359-365.
   PubMed Web of Science ®Google Scholar
• MALACCO E, MARCIA G, RAPELLI A, MENOTTI A, ZUCCARO M, COPPINI A: Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. (2003) 12(3):160-167.
   PubMed Web of Science ®Google Scholar
• ROSEI EA, DAL PALÙ C, LEONETTI G, MAGNINI B, PESSINA A, ZANCHETTI A ON BEHALF OF THE VHAS INVESTIGATORS: Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J. Hypertens. (1997) 15(11):1337-1344.
   PubMed Web of Science ®Google Scholar
• BORHANI NO, MERCURI M, BORHANI PA et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA (1996) 276(10):785-791.
   PubMed Web of Science ®Google Scholar
• PEPINE CJ, HANDBERG EM, COOPER-DEHOFF RM et al.: A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandilopril Study (INVEST): a randomized controlled clinical trial. JAMA (2003) 290(21):2805-2816.
   PubMed Web of Science ®Google Scholar
• WRIGHT JT JR, DUNN JK, CUTLER JA et al. FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Outcomes in hypertensive black and non-black patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 293(13):1595-1608.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, SEVER S, POULTER NR et al.: ASCOT Investigators: prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet (2005) 366(9489):895-906.
   PubMed Web of Science ®Google Scholar
• POULTER NR, WEDEL H, DAHLÖF B FOR THE ASCOT Investigators: Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet (2005) 366(9489):907-913.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, BIRKENHÄGER WH: Evidence that new antihypertensives are superior to older drugs. Lancet (2005) 366(9489):869-871.
   PubMed Web of Science ®Google Scholar
• BLACK HR, ELLIOTT WJ, GRANDITS G FOR THE CONVINCE RESEARCH GROUP: Results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. J. Hypertens. (2005) 23(5):1099-1106.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A, AGABITI-ROSEI E, DAL PALU C, LEONETTI G, MAGNANI B, PESSINA A: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomised treatment with either verapamil J Hypertens. (1998) 16(11):1667-1676.
   PubMed Web of Science ®Google Scholar
• AGODOA LY, APPEL L, BAKRIS GL et al.: Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA (2001) 285(21):2719-2728.
   PubMed Web of Science ®Google Scholar
• WRIGHT JT JR, BAKRIS G, GREEN T et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 288(19):2421-2431.
   PubMed Web of Science ®Google Scholar
• CRISTOFORI P, LANZONI A, QUARTAROLI M et al.: The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apo E-deficient mouse. J. Hypertens. (2000) 18(10):1429-1438.
   PubMed Web of Science ®Google Scholar
• TADDEI S, VIRDIS A, GHIADONI I et al.: Effect of calcium antagonist or beta blockade treatment on nitric-oxide dependent vasodilatation and oxidative stress in essential hypertensive patients. J. Hypertens. (2001) 19(8):1379-1386.
   PubMed Web of Science ®Google Scholar
• ESTACIO RO, JEFFERS BW, HIATT MR, BIGGERSTAFF SL, GIFFORD N, SCHRIER RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. (1998) 338(10):645-652.
   PubMed Web of Science ®Google Scholar
• SCHRIER RW, ESTACIO RO: Additional follow-up from the ABCD trial in patients with Type 2 diabetes and hypertension. N. Engl. J. Med. (2000) 343(26):1969.
   PubMed Web of Science ®Google Scholar
• YUI Y, SUMIYOSHI T, KODAMA T et al.: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens. Res. (2004) 27(3):181-191.
   PubMed Web of Science ®Google Scholar
• SHINODA E, YUI Y, KODAMA K et al.: Quantitative angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B) side arm study). Hypertension (2005) 45(6):1153-1158.
   PubMed Web of Science ®Google Scholar
• KOSKINEN P, MANTTARI M, MANNINNEN V, HUTTUNEN JK, HEINONEN OP, FRICK MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care (1992) 15(7):820-825.
   PubMed Web of Science ®Google Scholar
• KUUSISTO J, MYKKANEN L, PYORALA K, LAASKO M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes (1994) 43(8):960-967.
   PubMed Web of Science ®Google Scholar
• AGABITI-ROSEI E, MORELLI P, RIZZONI D: Effect of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension. Blood Press. Suppl. (2005) 1:14-22.
   PubMedGoogle Scholar
• JULIUS S, KJELDSEN SE, WEBER M et al.: Outcomes in hypertensive patients at high *cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomized trial. Lancet (2004) 363(9426):2022-2031.
   PubMed Web of Science ®Google Scholar
• WEBER MA, JULIUS S, KJELDSEN et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet (2004) 363(9426):2049-2051.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of angiotensin-*receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345(12):851-860.
   PubMed Web of Science ®Google Scholar
• NEUTEL JM, GERMINO FW, SMITH D: comparison of monotherapy with irbesartan 150 or amlodipine 5 mg for treatment of mild-to-moderate hypertension. J. Angiotensin Aldosterone Syst. (2005) 6(2):84-89.
   PubMed Web of Science ®Google Scholar
• PUTNAM D, GRIFFIS D, MCLAUGHLIN TP, AROCHO R, TANG S: Impact of therapy initiation with amlodipine or losartan on hemodynamic endpoints for the JNC-VI blood pressure stage. Am. J. Therapeut. (2006) 13(2):94-100.
   PubMedGoogle Scholar
• BREWSTER LM, VAN MONTFRANS GA, KLEJINEN J: Systematic review: Antihypertensive drug therapy in black patients. Ann. Int. Med. (2004) 141(8):614-627.
   PubMed Web of Science ®Google Scholar
• MESSERLI FH, OPARIL S, FENG Z: Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazapril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am. J. Cardiol. (2000) 86(11):1182-1187.
   PubMed Web of Science ®Google Scholar
• JAMERSON KA, NWOSE O, JEAN-LOUIS L, SCHOFIELD L, PURKAYASTHA D, BARON M: Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel monotherapy in patients with stage 2 hypertension. Am. J. Hypertens. (2004) 17(6):495-501.
   Web of Science ®Google Scholar
• ZHANG X, XU X, NASJLETTI A, HINTZE TH: Amlodipine enhances NO production induced by an ACE inhibitor through kinin-mediated mechanism in canine coronary micro vessels. J. Cardiovasc. Pharmacol. (2000) 35(2):195-202.
   PubMed Web of Science ®Google Scholar
• BLANK R, LA SALLE J, REEVES R, MARONI J, TARASENKO L, SUN F: Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini Study): J. Clin. Hypertens. (2005) 7(5):264-273.
   PubMedGoogle Scholar
• JUKEMA JW, VAN DER HOORN JW: Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opin. Pharmacother. (2004) 5(2):459-468.
   PubMed Web of Science ®Google Scholar
• ANDREADIS EA, TSOUROUS GI, MARAKOMICELAKIS GE et al.: High-dose monotherapy versus low-dose combination therapy of calcium channel and angiotensin receptor blockers in mild to moderate hypertension. J. Hum. Hypertens. (2005) 19(6):491-496.
   PubMed Web of Science ®Google Scholar
• RUILOPE LM, HEINTZ D, BRANDÃO AA et al.: 24-hour ambulatory blood-pressure effects of valsartan & hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study. Blood Pressure Monitoring (2005) 10(12):85-91.
   Google Scholar
• FOGARI R, PRETI P, ZOPPI A et al.: Effect of telmisartan/hydochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. Am. J. Hypertens. (2005) 18(5):577-583.
   Web of Science ®Google Scholar
• STERGIOU GS, MAKRIS T, PAPAVASILIOU M, EFSTATHIOU S, MANOLIS A: Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J. Hypertens. (2005) 23(4):883-889.
   PubMed Web of Science ®Google Scholar
• WEIR MR, FERDINAND KC, FLACK JM et al: A noninferiority comparison of valsartan/hydrochlorothizide combination versus amlodipine in black hypertensives. Hypertension (2005) 46(3):506-513.
   Google Scholar
• FUJIKAWA K, HASEBE N, KIKUCHI K; NICE-COMBI STUDY GROUP: Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension- the Nifedipine and Candesartan Combination (NICE-Combi) Study. Hypertens. Res. (2005) 28(7):585-591.
   Web of Science ®Google Scholar
• FRISHMAN WH, HAINER JW, SUGG J FOR THE M-FACT STUDY GROUP: A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release. Am. J. Hypertens. (2006) 19(4):388-395.
   Web of Science ®Google Scholar
• KAESEMEYER WH, CARR AA, BOTTONI PB, PRISANT LM: Verapamil and nifedipine in combination for the treatment of hypertension. J. Clin. Pharmacol. (1994) 34(1):48-51.
   PubMed Web of Science ®Google Scholar
• SASEEN JJ, CARTER BL, BROWN TE, ELLIOTT WJ, BLACK HR: Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension (1996) 28(1):1099-114.
   Google Scholar
• HORTON R: Spinning the risks and benefits of calcium antagonists. Lancet (1995) 346(8975):586-587.
   PubMed Web of Science ®Google Scholar
• STASON WB, SCHMID CH, NIESZWIECKI D et al.: Safety of nifedipine in patients with hypertension: a meta analysis. Hypertension (1997) 30(1 Pt 1):7-14.
   PubMed Web of Science ®Google Scholar
• STASON WB, SCHMID CH, NIEDZWIECKI D et al. Safety of nifedipine in angina: a meta analysis. Hypertension (1999) 33(1):24-31.
   PubMed Web of Science ®Google Scholar
• LUBSEN J, WAGENER G, KIRWAN BA: ACTION (a Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. J. Hypertens. (2005) 23(3):641-648.
   PubMed Web of Science ®Google Scholar
• ELLIOTT WJ, BANDARI A: The role of calcium antagonists in stroke prevention. J. Clin. Hypertens. (2005) 7(Suppl. 1):5-8.
   Google Scholar
• SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (2005) 36(6):1218-1226.
   PubMed Web of Science ®Google Scholar
• OKUDA N, HATASHI T, MORI T et al.: Nifedipine enhances the cardioprotective effects of an angiotensin-II receptor blocker in an experimental animal model of heart failure. Hypertens. Res. (2005) 28(5):431-438.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB, ALONSO DR, LUTAS EM: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. (1986) 57(6):450-458.
   PubMed Web of Science ®Google Scholar
• KOREN MJ, DEVEREUX RB, CASALE PN, SAVAGE DD, LARAGH JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated hypertension. Ann. Int. Med. (1991) 114(5):345-352.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, PENNERT K, HANSSON L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens. (1992) 5(2):95-110.
   Web of Science ®Google Scholar
• SCHMIEDER RE, SCHLACH, KLINGBEIL AU, MARTUS P: Update on reversal of LVH in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol. Dial. Transplant (1998) 13(3):564-569.
   PubMed Web of Science ®Google Scholar
• LIEBSON PR, GRANDITS GA, DIANZUMBA S et al.: Comparison of five antihypertensive therapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation (1995) 91(3):698-706.
   PubMed Web of Science ®Google Scholar
• GOTTDIENER JS, REDA DJ, MASSIE BM, MATERSON BJ, WILLIAMS DW, ANDERSON RJ, FOR THE VA COOPERATIVE STUDY GROUP ON ANTIHYPERTENSIVE AGENTS: Effects of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. Circulation (1997) 95(8):2007-2014.
   PubMed Web of Science ®Google Scholar
• LEENEN FHH, FOURNEY A: Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. Am. J. Cardiol. (1996) 78(2):203-207.
   PubMed Web of Science ®Google Scholar
• DEVEREUX RB, PALMIERI V, SHARPE N et al.: Effects of once daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The prospective randomized enalapril study evaluating regression of left ventricular enlargement (PRESERVE) trial. Circulation (2001) 104(11):1248-1254.
   PubMed Web of Science ®Google Scholar
• KIDNEY DISEASE OUTCOMESQUALITY INITIATIVE (K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. (2004) 43(5 suppl 1):S1-S290.
   PubMed Web of Science ®Google Scholar
• TOTO RD: Management of hypertensive kidney disease: role of calcium channel blockers. J. Clin. Hypertens. (2005) 7:(Suppl. 1):15-20.
   PubMedGoogle Scholar
• RAHMAN M, PRESSEL S, DAVIS BR et al. FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann. Int. Med. (2006) 144(3):172-180.
   PubMed Web of Science ®Google Scholar
• KESTENBAUM B, GILLEN L, SHERRARD DJ, SELIGER S, BALL A, STEHMAN-BREEN C: Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. (2002) 61(6):2157-2164.
   PubMed Web of Science ®Google Scholar
• COOPER-DEHOFF RM, ARANDA JM Jr, GAXIOLA E et al.: Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients – findings from the International Verapamil SR/Trandolapril Study (INVEST). Am. Heart J. (2006) 151(5):1071-1079.
   Google Scholar
• BLOOD PRESSURE LOWERINGTRIALISTS COLLABORATION: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with diabetes mellitus: results of prospectively designed overview of randomized trials. Arch. Int. Med. (2005) 165(12);1410-1419.
   PubMedGoogle Scholar
• MAAS R, BÖGER RH: Antihypertensive therapy: special focus on drug interactions. Expert Opin. Drug Saf. (2003) 2(6):549-579.
   PubMedGoogle Scholar
• ABERNATHY DR, SCHWARTZ JB: Calcium-antagonist drugs. N. Engl. J. Med. (1999) 341(19):1447-1456.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, MANGRUM A, COPLEY JB, VICKNAIR N, SADLER R: Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African-Americans. Hypertension (1997) 29:744-750.
   PubMed Web of Science ®Google Scholar